MigraineMind research summary

Efficacy and Safety of 2 Rimegepant Dosing Regimens for the Prevention of Episodic Migraine: A Randomized Controlled Study.

Neurology | 2026

Clinical trial
AuthorsGoadsby PJ, Tassorelli C, Fountaine RJ, Antinew J, de Besi P
JournalNeurology
Publication year2026
PubMed ID43056654

Summary

This study tested the effectiveness and safety of rimegepant for preventing migraines. Researchers focused on two dosing schedules compared to a placebo. Participants were adults with episodic migraines, experiencing 4 to 14 attacks monthly. They were enrolled from outpatient and research sites across ten countries. After a 28-day observation period, participants were randomly assigned to one of three groups. One group received a placebo daily, another took rimegepant every other day, and the last group took it daily. The study lasted 12 weeks. Researchers measured the average number of migraine days each month. They used advanced statistical methods to analyze the results. The findings showed that rimegepant could significantly reduce migraine days for patients. This could offer a new option for those struggling with frequent migraines. The study highlights the need for effective treatments with fewer side effects. Clinical relevance: This research indicates that rimegepant may effectively reduce migraine frequency for patients.

Related migraine research topics

Original research

Read the original publication and review its full methods and findings on PubMed.

MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.